Ferring Pharmaceuticals announced that the European Commission (EC) has granted marketing authorisation for Rekovelle (follitropin delta), a human recombinant follicle...
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro f ertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. There is no clinical trial experience with REKOVELLE in the long GnRH agonist protocol (see section 5.1).